TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Marat Fudim, Md, Mhs
Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025

Medera Inc. announced positive interim data from its MUSIC-HFpEF Phase 1/2a clinical trial for a gene therapy treatment targeting heart failure with preserved ejection fraction (HFpEF), demonstrating a favorable safety profile and early clinical benefits in treated patients.

Insights
JPMpC   neutral

CEO's comments highlighted potential broader market risks, but not directly negative about the company itself


AZN   neutral

Mentioned as a collaborator in developing HFpEF disease model, with no specific performance details provided